Announcement
MKTUPDTE: BLT: BLIS M18 ACHIEVES US FDA GRAS "NO OBJECTION" STATUS
12:24pm
BLT
24/04/2019 12:24
MKTUPDTE
NOT PRICE SENSITIVE
REL: 1224 HRS Blis Technologies Limited
MKTUPDTE: BLT: BLIS M18 ACHIEVES US FDA GRAS "NO OBJECTION" STATUS
BLIS M18 TM Achieves US FDA GRAS "No Objection" status.
Blis Technologies Limited announces that their 2nd probiotic strain BLIS M18
TM, has had the issuance of a US Food and Drug Administration 'Letter of No
Objection'. This follows the BLIS K12 "Letter of No Objection" in 2016.
The Letter of No Objection, more commonly known as GRAS or 'Generally
Recognized As Safe', is another recognition of the robust data supporting
Blis probiotics.
It adds a new level of credibility for BLIS M18 TM and has the potential to
open opportunities with larger consumer food and beverage companies in the
US, but also is recognised as a relevant and credible safety assessment by
other countries and multinational companies.
Through the GRAS program, companies may submit their determination supported
by research and expert review that a specific ingredient is Generally
Recognized As Safe. The Letter of No Objection means that the FDA has
reviewed the data and has no questions regarding the notice submitted.
For further information please contact:
Brian Watson
CEO
027 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go
beyond the gut. Combining innovation with evidence-based research and the
highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad
breath), immune support and teeth and gum health. BLIS products are sold
throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.
End CA:00333667 For:BLT Type:MKTUPDTE Time:2019-04-24 12:24:55
Click here
to view related attachments.
